Despite initial encouraging results, preliminary results showed no significant differences in response between the MP and MP plus infliximab groups. In the M.D. Anderson phase III experience, the incidence of infection and causative organisms were similar in both groups, although an increased risk of fungalinfections has been recently reported, and cautious use of this agent should probably include antifungalprophyl axis . Despite encouraging response rates in the steroid-refractory setting, treatment of acute GVHD at an earlier stage with infliximab did not prove more effective than steroids alone. Once established, GVHD continues to be the main cause of death.
Bibliographical noteFunding Information:
This work was supported by grant nos. HL070149, CA18029, and HL36444 from the National Institutes of Health (Bethesda, MD).